全球周围神经病变市场行业概况及 2031 年预测 - 市场分析和市场份额

全球周围神经病变市场概览

周围神经病变是一种脑部和脊髓以外的神经（周围神经）受损时发生的疾病。由于糖尿病（周围神经病变的主要原因）发病率上升以及人口老龄化，全球周围神经病变市场正在扩大。例如，世界卫生组织估计，全球有超过 4.22 亿人患有糖尿病，这大大增加了周围神经病变的患病率。随着人们认识的提高和神经传导研究和神经成像等诊断技术的进步，早期检测和治疗效果正在改善。

本市场报告详细介绍了最新发展、市场份额、基于细分和区域分析的市场趋势、市场领导者的影响、新兴收入领域的机会分析、市场法规、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地理扩展和市场技术创新。要获取有关市场的更多信息，请联系 Data Bridge Market Research 的专家分析师团队。我们的团队将帮助您做出明智的市场决策，以实现市场增长。

全球周围神经病变市场规模

诊断技术和创新疗法的进步显著提高了周围神经病变的治疗效果。尖端诊断工具（例如高分辨率神经传导研究和先进的神经成像技术）能够更精确地检测和评估神经损伤。因此，Databridge Market Research 深入全面分析了市场，并发现全球周围神经病变产品市场正以 4.40% 的复合年增长率增长。2023 年市场规模价值为 2.8631 亿美元，预计到 2031 年将增长至 4.0406 亿美元。

全球周围神经病变市场动态

全球周围神经病变市场的增长动力

糖尿病病例增加

The rise in diabetes cases is a major driver of growth in the global peripheral neuropathy market. As diabetes prevalence increases—affecting over 422 million people globally (WHO)—the incidence of peripheral neuropathy, a common complication of the disease, is also on the rise. This growing demand for effective management of nerve damage is spurring advancements in diagnostic technologies and innovative treatments. Consequently, the expanding diabetic population is significantly contributing to the increased need for peripheral neuropathy solutions and driving market growth.

Aging Population

With approximately 1.5 billion people aged 65 and older projected by 2050, age-related conditions, including peripheral neuropathy, are becoming increasingly prevalent. The rising number of elderly individuals intensifies the demand for advanced diagnostic tools and effective treatments tailored to manage and alleviate peripheral neuropathy. Consequently, the healthcare industry is responding to this growing need with innovations and expanded market offerings, further propelling Global Peripheral Neuropathy Market Growth.

Peripheral Neuropathy Market Growth Opportunities

Emergence of innovative diagnostic technologies

The emergence of innovative diagnostic technologies, including high-resolution nerve conduction studies and sophisticated neuroimaging techniques, is creating substantial growth opportunities within the global peripheral neuropathy market. These advancements enable earlier and more precise diagnosis of nerve damage, which improves treatment outcomes and increases demand for specialized care. As a result, healthcare providers are investing more in these technologies, driving global peripheral neuropathy market expansion.

Digital Health Integration

According to the National Institute of Neurological Disorders and Stroke (NINDS), peripheral neuropathy affects approximately 20 million people in the United States alone, but many cases remain undiagnosed due to lack of awareness. Improved awareness has resulted in higher diagnosis rates, with studies indicating that increased education about symptoms and treatment options correlates with a rise in clinical consultations and demand for specialized therapies. This heightened awareness is fueling market expansion by prompting more individuals to seek diagnosis and treatment, thereby driving the growth of peripheral neuropathy-related healthcare products and services.

Peripheral Neuropathy Market Growth Challenges

High Treatment Costs

The expenses associated with advanced diagnostic instruments and cutting-edge therapies for peripheral neuropathy can be considerable, which may hinder accessibility and impact market expansion. For instance, neurostimulation devices, such as the Axon Therapy System, may be priced at over $20,000 per unit, while personalized treatment options, including targeted gene therapies, can surpass $100,000 per patient on an annual basis. Such elevated costs can pose significant challenges for both patients and healthcare systems, especially in areas with constrained healthcare budgets or limited insurance coverage. Consequently, the financial strain may limit patient access to effective treatments and impede overall market development.

Diagnostic Complexity

The nonspecific and overlapping symptoms of peripheral neuropathy, which can mimic other neurological or systemic conditions, contribute to significant diagnostic challenges. For instance, diabetic neuropathy shares symptoms with conditions like carpal tunnel syndrome and multiple sclerosis, complicating accurate diagnosis without extensive testing. This diagnostic complexity not only impacts patient outcomes but also hampers the growth of the global peripheral neuropathy market. Misdiagnoses or delays in treatment can lead to reduced demand for targeted therapies and diagnostic tools, ultimately stunting market expansion and innovation.

Peripheral Neuropathy Market Size Growth Restraints 

Regulatory Complexity acting as a Barrier to Peripheral Neuropathy Market Growth

The growth of the peripheral neuropathy market is also constrained by stringent government regulations, which can delay the approval and commercialization of new therapies and diagnostic tools. Regulatory agencies, such as the FDA in the United States and the EMA in Europe, impose rigorous standards for clinical trials, safety, and efficacy, often leading to extended timelines for product approval. These regulatory hurdles not only increase the cost of bringing new treatments to market but also limit the availability of innovative therapies for patients. Consequently, the market faces challenges in achieving rapid growth, as companies must navigate complex regulatory landscapes that can stifle the development and distribution of essential medical advancements.

Peripheral Neuropathy Market Scope and Trends

• The approval of new extended-release formulations of anti-seizure medications, such as gabapentin and pregabalin, has improved the management of peripheral neuropathy. These formulations provide more consistent pain relief with fewer doses, enhancing patient adherence and treatment outcomes.
• Advances in TENS technology, including more portable and user-friendly devices, have enhanced the accessibility and effectiveness of this therapy. These improvements allow for better pain management at home, making it a more attractive option for patients seeking non-invasive treatment alternatives.
• The rise of digital health technologies and telemedicine has facilitated better homecare management for peripheral neuropathy. Remote monitoring tools and telehealth consultations enable patients to receive ongoing support and adjust their treatments from home, improving overall management and reducing the need for frequent hospital visits.
• The introduction of novel oral medications, such as extended-release formulations of antidepressants and anti-seizure drugs, has provided new options for managing peripheral neuropathy pain. These advancements help maintain consistent therapeutic levels, improving pain control and patient convenience.
• The growth of online pharmacies has made it easier for patients to access peripheral neuropathy medications and treatments. This development has increased the availability of both prescription and over-the-counter products, offering convenience and flexibility for patients managing their condition.

Peripheral Neuropathy Market Regional Analysis – Market Trends

Key Insights

• The U.S. and Canada have supportive regulatory frameworks that facilitate the approval and commercialization of new treatments. The Food and Drug Administration (FDA) and Health Canada are key players in ensuring that novel therapies and diagnostic tools reach the market efficiently.
• European regulatory agencies, such as the European Medicines Agency (EMA), play a crucial role in the approval and commercialization of new therapies. Key European markets, including Germany, France, and the UK, are leading in the adoption of advanced treatments and technologies.
• 亚太地区糖尿病的高发病率是周围神经病变市场的主要推动力。根据美国国家医学图书馆的数据，2000 年至 2035 年间，南亚 2 型糖尿病的发病率预计将增长 150% 以上，这反映出对新疗法和诊断解决方案的强劲需求。
• 非洲市场​​面临着诸多挑战，例如医疗保健服务有限、治疗可用性不稳定以及需要提高对周围神经病变的认识。然而，健康计划（非洲糖尿病护理计划）和医疗基础设施投资正在推动市场增长。

周围神经病变市场领先企业

• Teikoku Pharma USA, Inc（美国）
• 太阳制药工业有限公司 (印度)
• Galen Limited（美国）
• Cipher Pharmaceuticals Inc（加拿大）
• Mylan NV（美国）
• Aurobindo Pharma（印度）
• Zydus Cadila（印度）
• Hikma Pharmaceuticals PLC（英国）
• ACI 有限公司 (孟加拉国)
• Apotex Inc（加拿大）
• 强生服务公司（美国）
• 辉瑞公司 (美国)
• Arbor Pharmaceuticals（美国）
• ALMATICA PHARMA（印度）
• Alkem Labs（印度）
• Amneal Pharmaceuticals LLC（美国）
• 诺华公司（瑞士）
• 鲁冰花（印度）

全球周围神经病变市场最新发展

• 2024 年 7 月，美国食品药品监督管理局 (FDA) 批准了一种新型缓释普瑞巴林制剂，用于治疗周围神经病变疼痛。该批准代表了治疗慢性神经病变疼痛的重大进步。
• 2024 年 8 月，CMT 研究基金会 (CMTRF) 向位于美国全国儿童医院的一项研究计划分配资源，旨在创造创新方法来实施基因疗法，以治疗各种形式的夏科-马里-图斯病 (CMT)。
• 2024 年 6 月，总部位于艾哈迈达巴德的制药公司 CORONA Remedies 创下了亚洲纪录，在一周内使用生物振动计筛查了最多数量的周围神经病变患者。

DBMR 关于全球周围神经病变市场的市场报告将为您提供宝贵的见解，这些见解有助于您做出多项重要的业务决策。根据我们的报告和研究专业知识，您可以为您的业务制定切实可行的增长战略。

SKU-53041